121P Endocrine response assessment in HR+ HER2- early breast cancer: Concordance of central versus local Ki67 measurements in the ADAPTcycle trial

Moritz Hamann; Oleg Gluz; M Christgen; Ulrike Nitz; Sherko Kümmel; Michael Braun; M. Thill; Rachel Würstlein; Pauline Wimberger; Andreas D. Hartkopf; Christian Schem; Matthias Zaiß; M.K. Graeser-Mayer; R.E. Kates; Christine zu Eulenburg; Katarzyna Jóźwiak; S. Burmeister; R.F.L. Baehner; Hans Kreipe; N. Harbeck

doi:10.1016/j.esmoop.2024.103109

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

In ADAPTcycle, post-endocrine central Ki67 (Ki67post) ≤10% was defined as endocrine therapy response (ETR) to guide therapy decisions in HR+ HER2- EBC. Here, concordance between local and central Ki67 measurements was evaluated to assess the robustness of this factor for routine clinical application.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hamann et al. (2024) studied this question.

synapsesocial.com/papers/68e6c339b6db64358764281f https://doi.org/10.1016/j.esmoop.2024.103109

View Full Paper

Ask AI

Bookmark

Share

121P Endocrine response assessment in HR+ HER2- early breast cancer: Concordance of central versus local Ki67 measurements in the ADAPTcycle trial

Ask about this paper

Abstract

Discussion

Cite This Study

121P Endocrine response assessment in HR+ HER2- early breast cancer: Concordance of central versus local Ki67 measurements in the ADAPTcycle trial

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading